Article thumbnail
Location of Repository

Influence of Dendritic Cells on Viral Pathogenicity

By Giulia Freer and Donatella Matteucci

Abstract

Although most viral infections cause minor, if any, symptoms, a certain number result in serious illness. Viral disease symptoms result both from direct viral replication within host cells and from indirect immunopathological consequences. Dendritic cells (DCs) are key determinants of viral disease outcome; they activate immune responses during viral infection and direct T cells toward distinct T helper type responses. Certain viruses are able to skew cytokine secretion by DCs inducing and/or downregulating the immune system with the aim of facilitating and prolonging release of progeny. Thus, the interaction of DCs with viruses most often results in the absence of disease or complete recovery when natural functions of DCs prevail, but may lead to chronic illness or death when these functions are outmanoeuvred by viruses in the exploitation of DCs

Topics: Review
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2712770
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). A blunted blood plasmacytoid dendritic cell response to an acute systemic viral infection is associated with increased disease severity.
  2. (2007). A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
  3. (2006). A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA.
  4. (2007). Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication.
  5. (2007). Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DCSIGNR.
  6. (2007). C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB.
  7. (2006). CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection.
  8. (2008). Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells.
  9. (2005). Cell-type specific involvement of RIG-I in antiviral response.
  10. (2003). Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo.
  11. (2008). Cutting edge: Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo.
  12. (2005). Dancing with the enemy: the interplay of herpes simplex virus with dendritic cells.
  13. (2006). DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.
  14. (2008). DCSIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog 4: e1000049. doi:10.1371/ journal.ppat.1000049.
  15. (2006). DCSIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages.
  16. (2007). DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.
  17. (2005). Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection.
  18. (2008). Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PDL1/PD-1 pathway.
  19. (2005). Dendritic cell-mediated T cell polarization.
  20. (2007). Dendritic cells: understanding immunogenicity.
  21. (2007). Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
  22. (2003). Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses.
  23. (2007). Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking.
  24. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.
  25. (2008). Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.
  26. (2008). Distinct roles for DC-SIGN +-dendritic cells and Langerhans cells in HIV-1 transmission.
  27. (2007). Duration, combination and timing: the signal integration model of dendritic cell activation.
  28. (2007). Effects of feline immunodeficiency virus on feline monocyte-derived dendritic cells infected by spinoculation.
  29. (2008). Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.
  30. (2006). Geijtenbeek TB
  31. (2005). Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use.
  32. (2006). Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection.
  33. (2003). Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR.
  34. (2008). Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production.
  35. (2007). Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.
  36. (2008). HIV transfer between CD4 T cells does not require LFA1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4.
  37. (2006). HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood.
  38. (2008). Host immunity during RSV pathogenesis.
  39. (2005). Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells.
  40. (2008). Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
  41. (2006). Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.
  42. (2001). Immature monocyte derived dendritic cells are productively infected with herpes simplex virus type 1.
  43. (2007). Immune synapses formed with measles virus-infected dendritic cells are unstable and fail to sustain T cell activation.
  44. (2008). Immunotherapy with internally inactivated virus loaded dendritic cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course.
  45. (2007). Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis.
  46. (2007). Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia.
  47. (2002). Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs.
  48. (2006). Influenza virus evades innate and adaptive immunity via the NS1 protein.
  49. (2007). Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.
  50. (2007). Krug A
  51. (2004). L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.
  52. (2001). Langerhans cells and the cells of Langerhans cell histiocytosis do not express DC-SIGN.
  53. (2007). Langerin is a natural barrier to HIV-1 transmission by Langerhans cells.
  54. (2007). Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells.
  55. (2001). Loss of blood CD11c(+) myeloid and CD11c(2) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load.
  56. (2007). Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.
  57. (2008). Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells.
  58. (2005). Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections.
  59. (2003). Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity.
  60. (2008). Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors.
  61. (2004). pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN.
  62. (2008). Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection.
  63. (2000). Primate cytomegaloviruses encode and express an IL-10-like protein.
  64. (2008). Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.
  65. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
  66. (2001). Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3.
  67. (2008). Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells.
  68. (2004). Respiratory syncytial virus, pneumonia virus of mice, and influenza A virus differently affect respiratory allergy in mice.
  69. (2005). Respiratory viral infections and asthma pathogenesis: a critical role for dendritic cells?
  70. (2006). RIG-Imediated antiviral responses to single-stranded RNA bearing 59-phosphates.
  71. (2006). Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine.
  72. (2008). Role of dendritic cells in antibody dependent enhancement of dengue infection.
  73. (2007). Semenderived amyloid fibrils drastically enhance HIV infection.
  74. (2004). Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and
  75. (2004). Steinkasserer A
  76. (2008). Targeting the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
  77. (2008). The Achilles heel of the Trojan Horse model of HIV-1 trans-infection. PLoS Pathog 4: e1000051. doi:10.1371/ journal.ppat.1000051.
  78. (2008). The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections.
  79. (2008). The Ctype lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways.
  80. (2000). The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments.
  81. (2008). Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
  82. (2006). TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity.
  83. (2007). Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity.
  84. (2007). Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.
  85. (2004). Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.